PrecisemAb Biotech was honored to participate in the final pitch of the inaugural PharmaEssentia Innovation Award in Tokyo, joining innovative biotech teams from Taiwan and Japan to showcase emerging technologies with global development potential.
Throughout the preparation process, from refining our scientific narrative and consolidating development data to delivering the final presentation, our team continued to focus on one central question: how to translate innovative antibody engineering technologies into next-generation therapeutics with meaningful clinical value and global development potential.
The final pitch provided PrecisemAb Biotech with a valuable opportunity to present our Universal Antibody Lock platform and the development progress of our lead programs, including PSM101, to international judges and industry partners. The insightful feedback we received also helped us further refine our technology positioning, development strategy, and global partnership direction.
We sincerely thank the judging committee for their recognition and valuable guidance, as well as PharmaEssentia and TECH Tokyo for creating a meaningful platform that promotes cross-border biotech innovation between Taiwan and Japan. This experience not only enabled our team to engage with international ecosystem partners, but also further validated the global potential of our Antibody Lock platform.
Moving forward, PrecisemAb Biotech will continue advancing its Universal Antibody Lock technology platform and core programs such as PSM101, with the goal of bringing safer and more disease-selective antibody therapeutics toward international collaboration and clinical translation.
NEWS: Global BIO